{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:27:33Z","timestamp":1790706453770,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014481","name":"Kite Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014481","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s12325-022-02201-6","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T13:05:21Z","timestamp":1655816721000},"page":"3678-3695","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cost-Effectiveness of KTE-X19 for Adults with Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States"],"prefix":"10.1007","volume":"39","author":[{"given":"Bijal D.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoling","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushanth","family":"Jeyakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Gabriel","family":"Castaigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imi","family":"Faghmous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad Kharabi","family":"Masouleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Malone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"issue":"1","key":"2201_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"2201_CR2","doi-asserted-by":"publisher","first-page":"S455","DOI":"10.1016\/j.jval.2020.08.320","volume":"23","author":"J Spoorendonk","year":"2020","unstructured":"Spoorendonk J, Feng C, Shah D, et al. PCN183 global incidence, prevalence, and survival in relapsed\/refractory (R\/R) adult acute lymphoblastic leukemia (aALL): a systematic literature review (SLR). Value Health. 2020;23:S455.","journal-title":"Value Health"},{"key":"2201_CR3","unstructured":"National Cancer Institute. SEER Cancer Statistics Review (CSR) 1975\u20132018. In: Howlader N, Noone A, Krapcho M, et al., editors. SEER Cancer Statistics Review (CSR) 1975-2018. Bethesda, 2021."},{"issue":"14","key":"2201_CR4","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.32116","volume":"125","author":"HM Kantarjian","year":"2019","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125(14):2474\u201387.","journal-title":"Cancer"},{"issue":"9","key":"2201_CR5","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347.","journal-title":"N Engl J Med"},{"issue":"1","key":"2201_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-020-00905-2","volume":"13","author":"B Samra","year":"2020","unstructured":"Samra B, Jabbour E, Ravandi F, et al. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020;13(1):70.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2201_CR7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2141.2010.08246.x","volume":"150","author":"JM Rowe","year":"2010","unstructured":"Rowe JM. Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol. 2010;150(4):389\u2013405.","journal-title":"Br J Haematol"},{"issue":"4","key":"2201_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3322\/caac.21342","volume":"66","author":"D Sarfati","year":"2016","unstructured":"Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. CA Cancer J Clin. 2016;66(4):337\u201350.","journal-title":"CA Cancer J Clin"},{"key":"2201_CR9","first-page":"963689720919434","volume":"29","author":"F Zhu","year":"2020","unstructured":"Zhu F, Wei G, Zhang M, et al. Factors associated with costs in chimeric antigen receptor T-cell therapy for patients with relapsed\/refractory B-cell malignancies. Cell Transplant. 2020;29:963689720919434.","journal-title":"Cell Transplant"},{"issue":"5","key":"2201_CR10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/14737167.2018.1490645","volume":"18","author":"X Zhang","year":"2018","unstructured":"Zhang X, Song X, Lopez-Gonzalez L, et al. Economic burden associated with adverse events of special interest in patients with relapsed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the United States. Expert Rev Pharmacoecon Outcomes Res. 2018;18(5):573\u201380.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2201_CR11","doi-asserted-by":"crossref","unstructured":"Cool C, Feng C, Wade S, et al. Healthcare resource utilization and costs in adult patients with relapsed or refractory acute lymphoblastic leukemia using real-world data from the United States. In: Pan Pacific Lymphoma Conference; Big Island, Hawaii 2021.","DOI":"10.1002\/hon.106_2881"},{"issue":"10","key":"2201_CR12","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.clinthera.2018.08.005","volume":"40","author":"X Zhang","year":"2018","unstructured":"Zhang X, Song X, Lopez-Gonzalez L, et al. Economic burden of veno-occlusive disease in patients with B-cell acute lymphoblastic leukemia in the United States. Clin Ther. 2018;40(10):1711\u20131719.e1.","journal-title":"Clin Ther"},{"key":"2201_CR13","unstructured":"Food and Drug Administration. TECARTUS: Highlights of prescribing information. 2021. https:\/\/www.fda.gov\/media\/140409\/download."},{"issue":"10299","key":"2201_CR14","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. The Lancet. 2021;398(10299):491\u2013502.","journal-title":"The Lancet"},{"issue":"9","key":"2201_CR15","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","volume":"19","author":"PA Brown","year":"2021","unstructured":"Brown PA, Shah B, Advani A, et al. Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;19(9):1079\u2013109.","journal-title":"J Natl Compr Cancer Netw."},{"key":"2201_CR16","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost effectiveness in health and medicine","author":"MRSJ Gold","year":"1996","unstructured":"Gold MRSJ, Russell LB, Weinstein MC. Cost effectiveness in health and medicine. New York: Oxford University Press; 1996."},{"issue":"5","key":"2201_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1177\/0272989X12454577","volume":"32","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices\u2013overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making. 2012;32(5):667\u201377.","journal-title":"Med Decis Making"},{"key":"2201_CR18","unstructured":"Institute for Clinical and Econoc Review. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: Effectiveness and Value. Final Evidence Report. In: California Technology Assessment Forum, editor. 2018. https:\/\/collections.nlm.nih.gov\/catalog\/nlm:nlmuid-101744954-pdf"},{"issue":"1","key":"2201_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9.","journal-title":"BMC Med Res Methodol"},{"key":"2201_CR20","unstructured":"flexsurv. Flexible parametric survival and multi-state models. 2021. https:\/\/cran.rproject.org\/web\/packages\/flexsurv\/flexsurv.pdf"},{"issue":"3","key":"2201_CR21","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1093\/biostatistics\/kxl030","volume":"8","author":"PC Lambert","year":"2007","unstructured":"Lambert PC, Thompson JR, Weston CL, et al. Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics. 2007;8(3):576\u201394.","journal-title":"Biostatistics"},{"key":"2201_CR22","unstructured":"Social Security Administration. Actuarial Life Table 2017. https:\/\/www.ssa.gov\/OACT\/STATS\/table4c6_2017.html. Accessed 22 Apr 2021."},{"issue":"9","key":"2201_CR23","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s40273-019-00812-6","volume":"37","author":"TE Delea","year":"2019","unstructured":"Delea TE, Zhang X, Amdahl J, et al. Cost effectiveness of blinatumomab versus inotuzumab ozogamicin in adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in the United States. Pharmacoeconomics. 2019;37(9):1177\u201393.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"2201_CR24","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1634\/theoncologist.2018-0179","volume":"23","author":"ED Pulte","year":"2018","unstructured":"Pulte ED, Vallejo J, Przepiorka D, et al. FDA supplemental approval: blinatumomab for treatment of relapsed and refractory precursor B-cell acute lymphoblastic leukemia. Oncologist. 2018;23(11):1366\u201371.","journal-title":"Oncologist"},{"key":"2201_CR25","unstructured":"NICE-National Institute for Health and Care Excellence. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. [TA554]. 2018. https:\/\/www.nice.org.uk\/guidance\/ta554\/resources\/tisagenlecleucel-for-treating-relapsed-or-refractory-bcell-acutelymphoblastic-leukaemia-in-people-aged-up-to-25-years-pdf-82607021872837."},{"issue":"12","key":"2201_CR26","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","volume":"101","author":"N G\u00f6kbuget","year":"2016","unstructured":"G\u00f6kbuget N, Dombret H, Ribera J-M, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524\u201333.","journal-title":"Haematologica"},{"key":"2201_CR27","doi-asserted-by":"crossref","unstructured":"Shah B, Faghmous I, Whitmore J, et al. The comparison of KTE-X19 to current standards of care: a pre-specified synthetic control study utilizing individual patient level data from historical clinical trials (SCHOLAR-3). In: American Society of Hematology: Annual Meeting & Exposition; December 11\u201314, 2021; Atlanta, Georgia2021.","DOI":"10.1182\/blood-2021-146598"},{"issue":"5","key":"2201_CR28","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40264-018-0760-1","volume":"42","author":"A Stein","year":"2019","unstructured":"Stein A, Franklin JL, Chia VM, et al. Benefit-risk assessment of blinatumomab in the treatment of relapsed\/refractory B-cell precursor acute lymphoblastic leukemia. Drug Saf. 2019;42(5):587\u2013601.","journal-title":"Drug Saf"},{"key":"2201_CR29","unstructured":"US Bureau of Labor Statistics. Consumer price index for medical care services. 2021. https:\/\/www.bls.gov\/cpi\/."},{"key":"2201_CR30","unstructured":"KITE. A study evaluating brexucabtagene autoleucel (KTE-X19) in adult subjects with relapsed\/refractory B-precursor acute lymphoblastic leukemia (ZUMA-3). In: Data on file, editor."},{"key":"2201_CR31","unstructured":"IBM Micromedex RED BOOK. 2021. https:\/\/www.ibm.com\/products\/micromedex-red-book. Accessed 22 Apr 2021."},{"key":"2201_CR32","unstructured":"KITE. Expert clinical opinion, data on file."},{"key":"2201_CR33","unstructured":"CMS Laboratory Fee Schedule. 2021. Available from: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/ClinicalLabFeeSched"},{"key":"2201_CR34","unstructured":"CMS Physician Fee Schedule. 2021. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/PhysicianFeeSched. Accessed 22 Apr 2021."},{"issue":"6","key":"2201_CR35","doi-asserted-by":"publisher","first-page":"75s","DOI":"10.1200\/JOP.2011.000469","volume":"8","author":"B Chastek","year":"2012","unstructured":"Chastek B, Harley C, Kallich J, et al. Health care costs for patients with cancer at the end of life. J Oncol Pract. 2012;8(6):75s\u201380s.","journal-title":"J Oncol Pract"},{"issue":"6","key":"2201_CR36","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1177\/0272989X11401031","volume":"31","author":"PW Sullivan","year":"2011","unstructured":"Sullivan PW, Slejko JF, Sculpher MJ, et al. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making. 2011;31(6):800\u20134.","journal-title":"Med Decis Making"},{"issue":"3","key":"2201_CR37","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/cncr.11098","volume":"97","author":"L Sung","year":"2003","unstructured":"Sung L, Buckstein R, Doyle JJ, et al. Treatment options for patients with acute myeloid leukemia with a matched sibling donor: a decision analysis. Cancer. 2003;97(3):592\u2013600.","journal-title":"Cancer"},{"issue":"5","key":"2201_CR38","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2217\/cer-2019-0065","volume":"9","author":"JR Baumgardner","year":"2020","unstructured":"Baumgardner JR, Brauer MS, Zhang J, et al. CAR-T therapy and historical trends in effectiveness and cost\u2013effectiveness of oncology treatments. J Comp Effect Res. 2020;9(5):327\u201340.","journal-title":"J Comp Effect Res"},{"issue":"7","key":"2201_CR39","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/jnci\/djy193","volume":"111","author":"RR Sarkar","year":"2019","unstructured":"Sarkar RR, Gloude NJ, Schiff D, et al. Cost-effectiveness of chimeric antigen receptor T-Cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia. J Natl Cancer Inst. 2019;111(7):719\u201326.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2201_CR40","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/13696998.2021.1894158","volume":"24","author":"CL Simons","year":"2021","unstructured":"Simons CL, Malone D, Wang M, et al. Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed\/refractory mantle cell lymphoma in the United States. J Med Econ. 2021;24(1):421\u201331.","journal-title":"J Med Econ"},{"issue":"5","key":"2201_CR41","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"key":"2201_CR42","doi-asserted-by":"publisher","first-page":"S272","DOI":"10.1016\/S2152-2650(21)01658-X","volume":"21","author":"B Shah","year":"2021","unstructured":"Shah B, Smith N, Raad A, et al. ALL-190: cost-effectiveness of KTE-X19 for adult patients with relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL) in the United States. Clin Lymphoma Myeloma Leuk. 2021;21:S272\u20133.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2201_CR43","unstructured":"American Red Cross. Reimbursement Update. Available from: https:\/\/www.redcrossblood.org\/content\/dam\/redcrossblood\/forms-and-certificates\/hospitalreimbursementupdate_2019.pdf."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02201-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02201-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02201-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T13:56:18Z","timestamp":1700747778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02201-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["2201"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02201-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"assertion":[{"value":"20 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}